Diagnostic criteria for hereditary colorectal cancer (CRC) are complex. " Open-access " colonoscopy makes it challenging to identify who needs genetic evaluation, intensive surveillance, and screening for extracolonic tumors. Our aim was to develop a simple, preprocedural risk assessment tool to identify who may be at highest risk for CRC.
INTRODUCTION
Appropriate risk strati cation improves the overall e ciency and e ectiveness of endoscopic screening and surveillance for colorectal cancer (CRC) (1) . Use of colonoscopy for CRC screening has increased in the United States (2,3) and commonly targets individuals at average risk due to age, or those at moderate risk with a history of colon polyps or a family history of colonic neoplasia. However, as many as 10 % of CRC cases may be associated with an inherited syndrome (4) and intensive endoscopic surveillance along with genetic evaluation and predictive testing have been shown to reduce CRC-related morbidity and mortality (5 -7) . Although many physicians routinely ask patients about their family history of colon cancer, identifying the subset of individuals who may be at risk for a hereditary cancer syndrome is di cult because of multiple de ning criteria and the requirement of a detailed personal and family history assessment.
Clinical criteria to identify patients at risk for Lynch syndrome (LS) (also known as hereditary nonpolyposis colorectal cancer), the most common hereditary CRC syndrome, are widely accepted (8 -11) but both the Amsterdam Criteria and Bethesda Guidelines are cumbersome and impractical to routinely use in clinical practice, particularly in asymptomatic screening populations where the majority of individuals are not at risk for the disease. Recent studies have shown that gastroenterologists have di culty recognizing LS and recommend appropriate screening at very low rates (12, 13) . Patients a ected with familial adenomatous polyposis classically develop hundreds to thousands of colorectal adenomas at a young age and can be easily identi ed, but a subset of patients have a less obvious phenotype. Patients with 10 or more (but < 100) cumulative colorectal adenomas may have a variant of familial adenomatous polyposis called attenuated familial adenomatous polyposis. In addition, a recessive form of adenomatous polyposis has been described, which is due to mutations in the MYH gene ( " MYH associated polyposis " ). Although the true incidence of atypical forms of polyposis is unknown, gene mutations in both APC and MYH are associated with a high CRC risk and should be considered in individuals with multiple adenomas. Under-recognition of clinical criteria used to identify individuals with LS, attenuated familial adenomatous polyposis, and other polyposis syndromes leads to incomplete risk assessment with many potential repercussions for patients who may be at the highest risk of developing cancer.
National guidelines recommend genetic evaluation in individuals at high risk for CRC based on personal or family medical history (14) . Identifying gene carriers through predictive genetic testing improves the e ciency of cancer surveillance and helps identify which family members may require intense endoscopic evaluation versus those who can undergo screening at average risk intervals (15, 16) . However, referral rates for genetic evaluation are low (17) despite the estimated 20 % of all CRC patients diagnosed each year who meet revised Bethesda criteria (18 -20) .
Time constraints placed on today ' s busy healthcare providers increase the di culty of identifying patients at risk for hereditary CRC syndromes. In the setting of " open-access " colonoscopy, gastroenterologists meet patients just minutes before performing colonoscopy with little time to obtain the complete personal and family histories needed to properly assess CRC risk. Incomplete risk assessment inevitably leads to inappropriate recommendations for surveillance colonoscopy and a missed opportunity for genetic evaluation referral. e goal of our study was to develop a simple, practical, and e cient tool to improve preprocedural CRC risk assessment by identifying those individuals who may be at high risk for hereditary CRC syndromes.
METHODS
e study proceeded in the following ve phases: (1) pilot testing of the data collection instrument; (2) data collection phase, where patients undergoing lower endoscopy completed a questionnaire and were risk strati ed based on personal or family history characteristics; individuals were classi ed as being " high risk " if they ful lled one of the nine prede ned criteria; (3) development of the CRC Risk Assessment Tool, where recursive partitioning analysis was used to derive an algorithm that would identify the most high-risk individuals with the fewest number of questions; (4) Eligible subjects included those who were scheduled for colonoscopy or exible sigmoidoscopy performed for screening, surveillance, or diagnostic purposes. All subjects were 18 years and older and were able to give informed consent. Exclusion criteria included the inability to read and write in English, as all subjects were required to complete a self-administered written questionnaire.
Potential participants were identi ed from the endoscopy center schedules and were invited to participate by mail before their procedure. Because this type of mailing required identication of potential subjects in advance, a waiver of consent from the Institutional Review Board was obtained for the initial part of recruitment. e potential study subjects received a cover letter describing the study, a study questionnaire, and consent form.
ose patients who were interested in participating completed the questionnaire before their procedure date and returned the completed study materials on the day of their examination.
Phases 1 and 2: instrument development and data collection
All recruited subjects completed the " CRC Risk Assessment Questionnaire, " a 34-item self-administered survey developed to assess CRC risk based on personal and family histories of CRC and polyps, as well as LS-related malignancies. e questionnaire also elicited information about subjects ' history of lower endoscopies, including number of procedures and the indication for the procedures. Standard demographic information such as age, gender, race -ethnicity, marital status, income, level of education, and type of health insurance was also obtained.
is study instrument was developed in collaboration with the hereditary colon cancer group at Dana-Farber Cancer Institute and within the Division of Gastroenterology at Brigham and Women ' s Hospital. e CRC Risk Assessment Questionnaire was pilot tested to determine whether participants found any questions di cult to understand. Seventy-one of 284 COLON/SMALL BOWEL Kastrinos et al. subjects were part of the pilot testing and were recruited from Brigham and Women ' s Hospital. Data from subjects enrolled in the pilot study were not included in the nal analysis and in generating the CRC Risk Assessment Tool.
Our goal was to identify a subset of individuals who may bene t from further risk assessment for hereditary CRC. We developed a category of " high-risk " that was de ned by criteria adapted from the modi ed and revised Bethesda guidelines (8 -11) as well as the American Gastroenterological Association ' s review on hereditary CRC and genetic testing (14) . Subjects reporting any of the following criteria were classi ed as high-risk: Personal history of CRC diagnosed at age < 50 years, polyps at age < 50 years, endometrial cancer at age < 50 years, any LS-associated cancer diagnosed at age < 50 years, ≥ 10 cumulative polyps; family history of rstdegree relative (FDR) with CRC at age < 50 years, FDR with polyps at age < 50 years, ≥ 3 relatives with CRC, FDR with LS-associated cancer at age < 50 years. LS-associated cancers include endometrial, ovarian, urinary tract (including bladder, ureter, kidney), gastric, small bowel, biliary, pancreatic, or brain cancers.
e proportion of individuals ful lling any high-risk criteria was calculated. To verify the accuracy of self-reported personal and family histories, those subjects who were classi ed as high risk and provided consent for future participation in the study, were contacted by telephone by the study ' s research coordinator. e information provided on the " CRC Risk Assessment Questionnaire " was reviewed for each individual high-risk subject to assess the accuracy of the histories provided. Simple descriptive statistics were used for the analysis of patient demographics and the proportion of subjects ful lling each high-risk criterion.
Phase 3: derivation of the CRC Risk Assessment Tool
We next analyzed data from the subject-completed questionnaires to construct a Risk Assessment Tool that would identify the greatest number of high-risk individuals with the fewest possible number of questions. rough recursive partitioning analysis (using Classi cation And Regression Tree so ware) (21) , a simple decision-making tool to identify high-risk individuals was derived. In this analysis, subgroups of patients ful lling high-risk criteria were identi ed in a sequential manner based on component criteria used to de ne high risk. e initial high-risk subgroup was based on one of the nine clinical factors deemed to be the single, most informative high-risk criterion. e presence of this rst criterion de ned the subgroup with the largest percentage of high-risk subjects. Once this criterion was identi ed, the remaining subject sample was divided again using the next best criterion. is process was repeated using subsequently chosen criterion until no further partitioning was useful.
rough recursive partitioning analysis, we developed an algorithm of the fewest number of questions that would identify the largest proportion of individuals ful lling high-risk criteria. We analyzed the ability of each potential criterion to identify the greatest proportion of high-risk individuals and determined which criteria would provide the maximum sensitivity in correctly stratifying subjects into the high-risk group.
Phase 4: validation testing of the CRC Risk Assessment Tool
e goal of the validation phase was to prospectively evaluate the proportion of high-risk individuals and performance of CRC Risk Assessment Tool in a second cohort from a di erent geographic location as well as practice setting. e validation cohort was comprised of consecutive individuals presenting for colonoscopy to any one of ve ambulatory centers a liated with Minnesota Gastroenterology, a large, privately held practice. e nine questions that were used to identify high-risk individuals were incorporated into each patient ' s preprocedural risk assessment evaluation (and electronic medical record). e necessary study data were obtained in a two-step manner. e patients were rst asked to complete a printed " History Form, " which is routinely sent by mail to all individuals scheduled for an endosocpic procedure at Minnesota Gastroenterology. e CRC Risk Assessment Tool questions were incorporated into the History Form. When patients presented for their scheduled colonoscopy, their responses to the History Form -CRC Risk Assessment Tool were then con rmed by either a nurse or an admission specialist during the admission (triage) process. No further attempts were made to verify the histories reported by eligible participants in the validation cohort. Information on the frequency of incorrect histories provided by study participants and elicited during the triage process was not recorded.
Data on patient age, gender, and responses to the nine questions were prospectively collected from May to September 2007 to validate the Risk Assessment Tool. e proportion of individuals ful lling high-risk criteria was calculated. Similar to the methods in the rst phase of the study, simple descriptive statistics were used to analyze patient demographics and the proportion of subjects ful lling each high-risk criterion. e sensitivity of each sequential question of the CRC Risk Assessment Tool was determined and compared with the ndings from the derivation cohort.
Phase 5: testing the ability of the CRC Risk Assessment Tool to identify individuals with LS and known MMR gene mutations
Subjects with a known mutation in the MMR genes most commonly associated with LS, MLH1 and MSH2 , were identied from an existing anonymized database of 1,914 unrelated probands who had undergone full gene sequencing and analysis of large rearrangements of these two genes by a commercial laboratory. is data has been used earlier to develop a prediction model to identify gene mutation carriers (22) . e database contains information on the probands ' demographic pro le (including age, gender, ethnicity) and personal and family histories of neoplasia (cancer and colonic adenomatous polyps) along with their ages of diagnoses. is information was originally provided on a test order form that was completed by the healthcare professional ordering the genetic testing. For phase 5 of this study, the personal and family histories of the identi ed mutation carriers were reviewed. e proportion of gene mutation carriers ful lling each sequential criterion of the CRC Risk Assessment Tool was calculated to determine the instrument ' s overall ability to accurately identify these individuals with LS.
RESULTS
A total of 1,641 patients met entry criteria during the recruitment period from February 2004 to September 2004 and were o ered enrollment in the study. Of these eligible subjects, 631 (38.5 % ) agreed to participate and returned completed questionnaires. A total of 16 patients were excluded: 11 had a known diagnosis of familial adenomatous polyposis or LS and ve provided incomplete questionnaires. Overall, data from 615 subjects were analyzed. A total of 327 patients enrolled at Brigham and Women ' s Hospital and 288 enrolled at Faulkner Hospital, and patient demographics were comparable between the two groups. Table 1 depicts subject demographics for the entire cohort and those subjects that ful lled high-risk criteria.
Of the 615 participants, 109 subjects (17.7 % ) met high-risk criteria. Detailed data regarding criteria by which they were de ned as high-risk are presented in Table 2 . A total of 84 of 109 subjects (77 % ) ful lled at least one criterion related to family history and 33 of 109 subjects (30.3 % ) ful lled at least one criterion related to their personal history. ere were eight patients who were de ned as being high-risk based on both personal and family histories. In all, 74 % (81 of 109) of high-risk participants had been scheduled for their lower endoscopy through " open-access " and had not seen a gastroenterologist before their procedure.
Attempts were made to contact the 55 subjects who were identi ed as high-risk and had given consent to be contacted by telephone for future participation in this study to verify the accuracy of the personal and family histories they had pro- subsequent question was ranked based on its ability to capture the most high-risk individuals remaining and yield the highest possible cumulative sensitivity when the questions were asked sequentially. e recursive partitioning technique initially segregated patients with history of a " FDR with a LS-associated cancer at age < 50 years " into the rst high-risk subgroup containing 31 of the 109 high-risk subjects (sensitivity = 28.4 % ), thereby making it the most informative question to ask when determining a patient ' s risk for a hereditary CRC syndrome. Among the remaining 584 subjects, " having more than three relatives with CRC " was the next selected criterion, identifying another 25 of the high-risk subjects (cumulative sensitivity = 51.4 % ). Certain criteria were then combined a priori to create single, two-part questions. For example, the criteria " FDR with CRC < 50 years " and " FDR with a LS-associated cancer at age < 50 years " were merged to create a single question, " Do you have a FDR with a LS-related cancer or CRC diagnosed before age 50? " resulting in a sensitivity of 43.1 % ( Figure 2 ) .
is was done to create questions that would be easier to ask and appear less redundant to patients. As a result, a total of six questions were used in the nal analysis, and the abbreviated algorithm is depicted in Figure 2 . e abbreviated algorithm was able to capture a higher percentage of high-risk individuals with each question when compared with the original algorithm that used all nine individual questions. e CRC Risk Assessment Tool was then extrapolated from the abbreviated algorithm and is comprised of the rst three questions of the algorithm, as these questions were deemed the most informative when asked in the given order. e decision to exclude the fourth question from the CRC Risk Assessment Tool ( " Do you have a FDR with colorectal polyps diagnosed before age 50? " ) was based on the assumption that the information provided on polyp history in family members may not be reliable. When asked in succession, the three-question Risk Assessment Tool is able to capture 77 % (sensitivity) of high-risk individuals. Figure 3 depicts the three-question CRC Risk Assessment Tool, as it would appear in the preprocedural evaluation of patients undergoing colonoscopy.
Data from 5,335 subjects were collected during the prospective validation phase. A total of 1,069 (20 % ) individuals met high-risk criteria. e mean age and gender of subjects in the derivation and validation cohorts was similar ( Table 1 ). e percentages of individuals ful lling each high-risk criterion in the derivation and validation cohort are shown in Table 2 .
e sensitivity of each criterion in the speci ed sequence was similar in both cohorts ( Figure 2 ). e three-question Risk Assessment Tool ' s ability to capture 77 % of individuals meeting high-risk criteria was reproduced in the validation cohort.
In a second external validation cohort, 285 individuals with LS (as de ned by clinical genetic testing and the presence of a mutation in the MMR genes MLH1 or MSH2 ) were identi ed. e percentages of gene mutation carriers ful lling each of the questions comprising the CRC Risk Assessment Tool are shown in Figure 4 . When asked in succession, the three-question vided. Twenty-three subjects were contacted successfully, and their personal and family histories were obtained and compared with the information these patients had provided on the CRC Risk Assessment Questionnaire. Eighty-seven percent (20 of 23) of these high-risk subjects reported the same personal and family history information.
Using recursive-partitioning analysis, the nine de ning criteria for high-risk were ranked from most informative to least informative in the form of a simple owchart ( Figure 1 ). e most informative question was that which identi ed the largest proportion of high-risk subjects. Each Eight patients were defi ned as high risk based on both personal and family history. c Twelve patients were defi ned as high risk based on both personal and family history.
d Percentages ( % ) related to personal and family history criteria correspond to proportion of high-risk individuals meeting each criterion.
Tool was able to accurately identify 95 % of gene mutation carriers. ere was little incremental value gained with proceeding to the fourth question of the validated Risk Assessment Tool, which captured < 1 % of additional mutation carriers. Data pertaining to the total number of polyps in mutation carriers were not available, and the cumulative sensitivity of the CRC Risk Assessment Tool could not be determined for this and subsequent criterion. Overall, only 5 % of individuals with LS would have been missed by the three-question CRC Risk Assessment Tool. a four-page preprocedural questionnaire that attempted to stratify patients at risk of having CRC or other signi cant pathology based on distal colonic symptoms. A weighted numerical score was subjectively derived by the investigators and relied solely on patient symptomatology. e impact of family history on risk strati cation was not incorporated into the questionnaire or scoring system. Church (24) took family history into account and designed a multivariable scoring system based solely on the presence of CRC in rst-and second-degree relatives to make risk more readily identi able. A disadvantage of such scoring systems is their complexity and the need of an additional nomogram reference to convert a point score to appreciable CRC risk.
To the best of our knowledge, this study is the rst study to generate a simple nonnumerical algorithm for CRC risk
DISCUSSION
We have developed a three-question CRC Risk Assessment Tool that will aid health care providers in identifying individuals who need further assessment for hereditary CRC and can be incorporated into the routine preprocedural evaluation for patients undergoing colonoscopy. e simple algorithm is comprised of the highest yield questions related to personal and family histories associated with an inherited form of CRC. Our goal was not to identify new risk factors or contest the importance of existing clinical criteria for LS or inherited polyposis syndromes but to derive a quick, practical approach to improve CRC risk assessment in identifying high-risk individuals.
To date, a limited number of scoring systems have been developed for CRC risk assessment. assessment. e main advantage of using the recursive partitioning approach is that it generates algorithms that are easy to apply in a variety of di erent clinical settings and can even be self-administered. is method has frequently been used to predict outcomes in other medical conditions, including neurological, oncological, as well as cardiac disorders, including acute coronary syndromes and congestive heart failure (25 -29) . In our analysis, recursive partitioning was used in a novel manner to create a hierarchy of importance among multiple criteria that are used to de ne the clinical outcome of high CRC risk. Our study has several important limitations. For the identication of high-risk individuals, we relied on the patients ' selfreport of their personal and family histories of CRC and polyps, as well as extracolonic cancers, as the gold standard. Although earlier studies have shown that histories reported by patients are accurate (30) and correct in up to 80 -89 % for colon cancer in FDRs (31 -33) , the provided information may be inaccurate, particularly polyp history of family members. Nevertheless, physicians commonly accept a patient ' s report of personal and family histories and in practice rarely have means to verify these medical histories, especially in an open-access endoscopy setting. e optimal use of the CRC Risk Assessment Tool is as a rst step in determining whether an individual may be at high risk for a hereditary CRC syndrome. If the Risk Assessment Tool " ags " such a patient, a detailed personal and multigenerational family history (pedigree) of neoplasia should be elicited and formal genetic assessment should be considered. Such an up evaluation of those individuals de ned as high-risk during the time of colonoscopy. Overall, the individuals who are identi ed by the CRC Risk Assessment Tool as high-risk should have one of the two evaluations a er colonoscopy. ose patients with a personal history of CRC at age < 50 years or a FDR with young-onset CRC or a LS-associated cancer should be referred for a genetic evaluation and possible predictive genetic testing or molecular tumor analysis. Patients with a personal history of young-onset adenomas or more than three relatives with CRC should undergo further clinical assessment to ascertain the histology, size, location, and number of polyps and to obtain a multigenerational family history of neoplasia. In all cases identi ed by the CRC Risk Assessment Tool, the percent likelihood of detecting a MMR mutation can be estimated by the user-friendly Web-based prediction model, PREMM 1,2 (22) . A PREMM 1,2 score of < 5 % has been considered to be a reliable cut-o to exclude those patients who do not need further risk assessment because of the model ' s 100 % negative predictive value for detecting germline MLH1 or MSH2 gene mutations (38) .
Our ndings have implications regarding the quality of care provided to patients presenting for open-access colonoscopy. Although much attention has been placed on the technical performance of colonoscopy for optimizing CRC screening, complete risk assessment and subsequent surveillance recommendations for patients and family members may be compromised in this type of setting. A limited encounter procedure may miss the subset of patients who are at highest risk of developing CRC. In this study, 74 % of the high-risk patients identi ed in the derivation cohort were scheduled for colonoscopy without a prior visit with a gastroenterologist. Although endoscopists have been criticized for the over-performance of colonoscopy in average and moderate risk individuals, there are no data available regarding the inappropriate under-use of colonoscopy in possible high-risk individuals. It has been established that referrals for genetic evaluation are low, even in individuals with a personal history of CRC who ful ll Bethesda criteria and have had close evaluation of personal and family histories. Colonoscopy performed through an open-access system may also contribute to the missed opportunity for genetic evaluation referral. Genetic counseling and predictive genetic testing is of particular importance in the care of a ected individuals and has been shown to increase life expectancy due to screening compliance or appropriate recommendations for surveillance or prophylactic surgery (39) among identied mutation carriers (40 -42) . Genetic testing also provides a ected individuals with information to help diagnose other family members, gain reassurance, engage in more informed health decision making, and plan for the future.
In summary, the high morbidity and mortality in patients with hereditary CRC syndromes provides compelling evidence for the need to apply a methodological approach to assessing CRC risk. In the age of open-access colonoscopy, gastroenterologists need to di erentiate patients who have a moderately increased risk of CRC from those who may be at high risk, need specialinstrument should aid in medical decision making regarding patients suspected of being at high risk for CRC and should enhance, not replace, physician assessment.
A second potential limitation of this study is related to response bias and the volunteer e ect. is is o en a limitation of survey studies, where it is di cult to tell whether the responses are typical of those that would be received of all persons who are eligible to participate. One may argue that the cohort from which the CRC Risk Assessment Tool was developed may have been skewed to include individuals that may have been more knowledgeable of their personal and family medical histories. However, the high percent of patients ful lling high-risk criteria in the validation cohort does not support this claim, as the nine questions that were used to de ne high-risk were a mandatory component of each patient ' s electronic medical record and were completed before the procedure. Overall, the results from the validation phase lend credence to the generalizability of the instrument, as its performance was reproducible with sustained discriminatory ability. Although subjects in the derivation cohort were of a higher socioeconomic status (36.5 % had household incomes > $ 100,000 and 65.8 % had college or postgraduate degrees) and were mostly Caucasian, further testing would be needed to determine the tool ' s performance in a more diverse patient population.
A third limitation of this study may be related to the criteria selected to de ne high-risk. e original nine questions de ning high-risk were adapted from the modi ed and revised Bethesda guidelines (8 -11) as well as the American Gastroenterological Association ' s review on hereditary CRC and genetic testing (14) . We deliberately chose to include less restrictive criteria that have been associated with LS to minimize the likelihood of missing high-risk subjects. For example, a personal history of an adenoma diagnosed at a young age is considered a criterion that when used alone has little capacity to identify an individual with a MMR gene. However, there is little information about the natural history of these young-onset polyps and there are currently no speci c recommendations to guide the clinical follow-up of such patients. In our opinion, it is reasonable for a young patient diagnosed with one or more adenomas to undergo additional clinical evaluation such as family history assessment, as well as review of the polyps removed to assess size, number, and presence of histologically advanced lesions.
e recognition of new polyposis phenotypes highlights the need for future study of individuals with young-onset adenomas and until additional information is made available, the current evaluation remains complex and an individualized process.
Finally, we do not have data on which of the patients identied by the CRC Risk Assessment Tool were found to ultimately have a hereditary cancer syndrome, as de ned by mutation analysis, which was not our outcome of interest. is tool was not developed to predict which patients may be mutation carriers of genes commonly associated with CRC. A number of sophisticated prediction models have been speci cally developed for such a purpose (22,34 -37) and may be used in conjunction with the CRC Risk Assessment Tool to streamline the follow-ized cancer surveillance and genetic counseling. e CRC Risk Assessment Tool is a simple, robust tool that is easy to use and has good, reproducible ability to identify individuals who may be at high risk of hereditary CRC and would bene t from a more thorough risk assessment to precisely determine appropriate CRC and extracolonic cancer surveillance recommendations.
CONFLICT OF INTEREST
Guarantor of the article: Sapna Syngal, MD, MPH. Speci c author contributions: Kastrinos: study concept and design, data acquisition, analysis and interpretation, and dra ing and critical revision of manuscript; Allen: data acquisition and critical revision of manuscript; Stockwell: study concept and design, data acquisition, and dra ing and critical revision of manuscript; Sto el: study concept and design, data interpretation, and critical revision of manuscript; Cook: data analysis and interpretation and critical revision of manuscript; Mutinga: data acquisition; Balma ñ a: data interpretation and critical revision of manuscript; Syngal: study concept and design, data interpretation, and critical revision of manuscript. 
